NO20043279L - Kombinasjoner som innbefatter epotiloner og antimetabolitter - Google Patents
Kombinasjoner som innbefatter epotiloner og antimetabolitterInfo
- Publication number
- NO20043279L NO20043279L NO20043279A NO20043279A NO20043279L NO 20043279 L NO20043279 L NO 20043279L NO 20043279 A NO20043279 A NO 20043279A NO 20043279 A NO20043279 A NO 20043279A NO 20043279 L NO20043279 L NO 20043279L
- Authority
- NO
- Norway
- Prior art keywords
- antimetabolites
- combinations
- epothilones
- include epothilones
- Prior art date
Links
- 230000000340 anti-metabolite Effects 0.000 title 1
- 229940100197 antimetabolite Drugs 0.000 title 1
- 239000002256 antimetabolite Substances 0.000 title 1
- 229930013356 epothilone Natural products 0.000 title 1
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34862202P | 2002-01-14 | 2002-01-14 | |
| US41617302P | 2002-10-04 | 2002-10-04 | |
| PCT/EP2003/000232 WO2003057217A1 (en) | 2002-01-14 | 2003-01-13 | Combinations comprising epothilones and anti-metabolites |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20043279L true NO20043279L (no) | 2004-08-05 |
Family
ID=26995808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20043279A NO20043279L (no) | 2002-01-14 | 2004-08-05 | Kombinasjoner som innbefatter epotiloner og antimetabolitter |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20060089327A1 (https=) |
| EP (2) | EP1469847A1 (https=) |
| JP (1) | JP2005513167A (https=) |
| KR (1) | KR20040078123A (https=) |
| CN (1) | CN1615136A (https=) |
| AU (1) | AU2003235761A1 (https=) |
| BR (1) | BR0306861A (https=) |
| CA (1) | CA2471509A1 (https=) |
| IL (1) | IL162595A0 (https=) |
| MX (1) | MXPA04006822A (https=) |
| NO (1) | NO20043279L (https=) |
| NZ (1) | NZ533940A (https=) |
| PL (1) | PL369670A1 (https=) |
| RU (1) | RU2346686C2 (https=) |
| TW (1) | TWI341728B (https=) |
| WO (1) | WO2003057217A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999001124A1 (en) | 1996-12-03 | 1999-01-14 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| US6204388B1 (en) | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| WO2002072085A1 (en) | 2001-03-14 | 2002-09-19 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| SK287334B6 (sk) * | 2001-03-19 | 2010-07-07 | Novartis Ag | Kombinácia protihnačkového činidla a epotilónu alebo jeho derivátu, farmaceutická kompozícia a obchodné balenie, ktoré ju obsahujú, a jej použitie |
| CA2499682A1 (en) * | 2002-10-09 | 2004-04-22 | Kosan Biosciences, Inc. | Epo d + 5-fu/gemcitabine |
| AU2004268377B2 (en) * | 2003-09-02 | 2008-06-26 | Novartis Ag | Cancer treatment with epothilones |
| US20050171167A1 (en) | 2003-11-04 | 2005-08-04 | Haby Thomas A. | Process and formulation containing epothilones and analogs thereof |
| US20060121511A1 (en) | 2004-11-30 | 2006-06-08 | Hyerim Lee | Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents |
| CA2645633A1 (en) * | 2006-04-05 | 2007-11-01 | Novartis Ag | Combinations of therapeutic agents for treating cancer |
| AU2007234379A1 (en) * | 2006-04-05 | 2007-10-11 | Novartis Ag. | Combinations of therapeutic agents for treating cancer |
| AU2011255647A1 (en) | 2010-05-18 | 2012-11-15 | Cerulean Pharma Inc. | Compositions and methods for treatment of autoimmune and other diseases |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2802005A (en) | 1957-08-06 | S-eluorourace | ||
| US2705727A (en) | 1952-07-10 | 1955-04-05 | Du Pont | Synthesis of ureas |
| US2933498A (en) | 1954-12-28 | 1960-04-19 | Burroughs Wellcome Co | 7-aminothiazolo-(5,4-d) pyrimidine |
| US3116282A (en) | 1960-04-27 | 1963-12-31 | Upjohn Co | Pyrimidine nucleosides and process |
| US4393064A (en) | 1976-03-05 | 1983-07-12 | Sri International | Process and composition for treatment of leukemia and process for preparing the same |
| US4357324A (en) | 1981-02-24 | 1982-11-02 | The United States Of America As Represented By The Department Of Health And Human Services | Prodrug derivatives of 9β-D-arabinofuranosyl-2-fluoroadenine |
| US4760135A (en) | 1984-09-06 | 1988-07-26 | University Of Kentucky Research Foundation | Phloretin and phlorizin derivative containing compounds |
| ATE92499T1 (de) * | 1984-12-04 | 1993-08-15 | Lilly Co Eli | Tumorbehandlung bei saeugetieren. |
| EP0239015B1 (en) | 1986-03-24 | 1991-10-16 | Nippon Kayaku Kabushiki Kaisha | Process for producing 1-beta-d-arabinofuranosylcytosine-5'-stearylphosphate monosodium salt and monohydrate thereof, and pharmaceutical composition containing the latter |
| NL194430C (nl) * | 1989-01-05 | 2002-04-04 | Otsuka Pharma Co Ltd | Niet-injecteerbaar farmaceutisch preparaat met anti-kankerwerking. |
| WO1992021345A1 (en) | 1991-05-27 | 1992-12-10 | Taiho Pharmaceutical Co., Ltd. | Composition, method and kit for potentiating antitumor activity and for curing tumor |
| DE4138042C2 (de) | 1991-11-19 | 1993-10-14 | Biotechnolog Forschung Gmbh | Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel |
| AU671491B2 (en) | 1992-12-18 | 1996-08-29 | F. Hoffmann-La Roche Ag | N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines |
| EP0923583A1 (de) | 1996-08-30 | 1999-06-23 | Novartis AG | Verfahren zur herstellung von epothilonen und zwischenprodukte innerhalb des verfahrens |
| DK1367057T3 (da) | 1996-11-18 | 2009-01-19 | Biotechnolog Forschung Gmbh | Epothiloner E og F |
| US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
| US6380394B1 (en) * | 1996-12-13 | 2002-04-30 | The Scripps Research Institute | Epothilone analogs |
| US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
| SK287775B6 (sk) | 1998-02-05 | 2011-09-05 | Novartis Ag | Farmaceutická formulácia obsahujúca epothilon, infúzny roztok a použitie farmaceutickej formulácie |
| US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
| DE69927790T2 (de) | 1998-02-25 | 2006-07-20 | Sloan-Kettering Institute For Cancer Research | Synthese von epothilonen, ihren zwischenprodukten und analogen verbindungen |
| FR2775187B1 (fr) * | 1998-02-25 | 2003-02-21 | Novartis Ag | Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo |
| US6302838B1 (en) * | 1998-02-25 | 2001-10-16 | Novartis Ag | Cancer treatment with epothilones |
| NZ511722A (en) | 1998-11-20 | 2004-05-28 | Kosan Biosciences Inc | Recombinant methods and materials for producing epothilone and epothilone derivatives |
| CN1122668C (zh) * | 1998-12-22 | 2003-10-01 | 诺瓦提斯公司 | 环氧噻酮衍生物，其制备方法及其药物组合物 |
| BR0008379A (pt) * | 1999-02-22 | 2002-09-24 | Biotechnolog Forschung Gmbh | Epotilonas modificadas em c-21 |
| US6664288B1 (en) * | 1999-04-14 | 2003-12-16 | Dana Farber Cancer Institute, Inc. | Method and composition for the treatment of cancer |
| GB9918429D0 (en) * | 1999-08-04 | 1999-10-06 | Novartis Ag | Organic compounds |
| AU2001266583A1 (en) * | 2000-05-26 | 2001-12-11 | Kosan Biosciences, Inc. | Epothilone derivatives and methods for making and using the same |
| WO2002072085A1 (en) * | 2001-03-14 | 2002-09-19 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| TWI287986B (en) * | 2001-12-13 | 2007-10-11 | Novartis Ag | Use of Epothilones for the treatment of the carcinoid syndrome |
-
2003
- 2003-01-13 AU AU2003235761A patent/AU2003235761A1/en not_active Abandoned
- 2003-01-13 WO PCT/EP2003/000232 patent/WO2003057217A1/en not_active Ceased
- 2003-01-13 CN CNA03802215XA patent/CN1615136A/zh active Pending
- 2003-01-13 MX MXPA04006822A patent/MXPA04006822A/es active IP Right Grant
- 2003-01-13 US US10/501,207 patent/US20060089327A1/en not_active Abandoned
- 2003-01-13 KR KR10-2004-7010853A patent/KR20040078123A/ko not_active Ceased
- 2003-01-13 TW TW092100606A patent/TWI341728B/zh not_active IP Right Cessation
- 2003-01-13 CA CA002471509A patent/CA2471509A1/en not_active Abandoned
- 2003-01-13 IL IL16259503A patent/IL162595A0/xx unknown
- 2003-01-13 RU RU2004124943/15A patent/RU2346686C2/ru not_active IP Right Cessation
- 2003-01-13 EP EP20030729249 patent/EP1469847A1/en not_active Ceased
- 2003-01-13 NZ NZ533940A patent/NZ533940A/en not_active IP Right Cessation
- 2003-01-13 BR BR0306861-7A patent/BR0306861A/pt not_active Application Discontinuation
- 2003-01-13 PL PL03369670A patent/PL369670A1/xx unknown
- 2003-01-13 EP EP08169239A patent/EP2030618A3/en not_active Withdrawn
- 2003-01-13 JP JP2003557575A patent/JP2005513167A/ja not_active Ceased
-
2004
- 2004-08-05 NO NO20043279A patent/NO20043279L/no not_active Application Discontinuation
-
2009
- 2009-08-12 US US12/539,891 patent/US20090298791A1/en not_active Abandoned
-
2010
- 2010-12-13 US US12/966,575 patent/US20110082101A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20060089327A1 (en) | 2006-04-27 |
| EP2030618A3 (en) | 2009-03-11 |
| MXPA04006822A (es) | 2004-12-08 |
| RU2346686C2 (ru) | 2009-02-20 |
| BR0306861A (pt) | 2004-11-03 |
| US20090298791A1 (en) | 2009-12-03 |
| PL369670A1 (en) | 2005-05-02 |
| JP2005513167A (ja) | 2005-05-12 |
| CN1615136A (zh) | 2005-05-11 |
| TWI341728B (en) | 2011-05-11 |
| KR20040078123A (ko) | 2004-09-08 |
| US20110082101A1 (en) | 2011-04-07 |
| EP1469847A1 (en) | 2004-10-27 |
| RU2004124943A (ru) | 2005-08-10 |
| IL162595A0 (en) | 2005-11-20 |
| CA2471509A1 (en) | 2003-07-17 |
| WO2003057217A1 (en) | 2003-07-17 |
| AU2003235761A1 (en) | 2003-07-24 |
| TW200306185A (en) | 2003-11-16 |
| EP2030618A2 (en) | 2009-03-04 |
| NZ533940A (en) | 2007-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3473251T3 (da) | Nikotin-cellulose-kombination | |
| DK1569712T3 (da) | Forbindelsesindretning | |
| IS2884B (is) | Kínasólínafleiður | |
| ATE318817T1 (de) | Aza-arylpiperazine | |
| DE50212360D1 (de) | Anfahrhilfesteuerungsvorrichtung | |
| DE50212349D1 (de) | Hirurgie | |
| DE50301200D1 (de) | Wischblatt | |
| ATE349458T1 (de) | Etonogestrelester | |
| DE60331717D1 (de) | Zündunterbrecherschaltkreis | |
| NO20043279L (no) | Kombinasjoner som innbefatter epotiloner og antimetabolitter | |
| ATA1572002A (de) | Managementspleisskassette | |
| DE50303404D1 (de) | Rückflussverhinderer | |
| DE50311365D1 (de) | Bohrvorrichtung | |
| DE50301960D1 (de) | Hydrolager | |
| DE50301464D1 (de) | Schraubensicherung | |
| ATA4142004A (de) | Trägerverbau | |
| DE50306167D1 (de) | Polyisocyanatharze | |
| DE50209283D1 (de) | Tropfbewässerungsrohr | |
| ATA19152002A (de) | Hubkupplung | |
| DE60311211D1 (de) | Zapfhahn | |
| ATE396192T1 (de) | N-sulfonylaminothiazole | |
| DE10244834B8 (de) | Suszeptometer | |
| FI113418B (fi) | Nimikilpi | |
| ATA16872002A (de) | Zwischenstück | |
| AT5889U3 (de) | Brennholzspleisser |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |